The valuation, as it is termed, is… expansive. A multiple of 388 times earnings, 116 times next year’s projections. These figures are not errors in calculation, but a reflection of expectations that defy conventional logic. And yet, one analyst, a Mr. Radke of Citi, maintains a ‘buy’ rating, suggesting that Palantir has, somehow, circumvented the established laws of financial gravity.
So, the question on everyone’s lips is this: is now the time to snatch up these discounted shares, or are we lookin’ at a fallin’ knife, best left alone? A body could lose a finger, or worse, a good portion of their savings, tryin’ to catch that one.
UPS recently unveiled its 2025 results – a curious blend of good, bad, and, dare I say, potentially great news. It’s a bit like inspecting a used automobile – you always find a few dents under the polish.
The Federal Reserve, in its infinite wisdom, has lately decided that low interest rates are no longer the fashionable pursuit, prompting a general retreat across the speculative domains of crypto. But while others merely blushed at the correction, Pi has positively fainted-dropping, like a poorly drafted love letter, to new depths with alarming regularity.
One is drawn to the dividend, not by its apparent generosity – a yield of 0.5% is hardly a beacon – but by its quiet insistence. It is a small sum, easily overlooked, yet it persists. The occasional special payments, these irregular disbursements, are not rewards, precisely, but rather acknowledgements of continued compliance with an unspoken contract. To consider this a viable income stream is to misunderstand its nature. It is, instead, a validation of one’s participation in a process whose logic is, at best, circular.
Apparently, the Centers for Medicare & Medicaid Services (CMS) is proposing a 0.09% increase in Medicare Advantage rates for 2027. Zero point zero nine. It’s less than the annual increase in my existential dread. Analysts were expecting 4-6%. It’s like ordering a pizza and getting a crouton. Not ideal. Humana (HUM 6.70%) and CVS Health (CVS +2.88%) also took a hit. It’s a reminder that in healthcare, “advantage” is a relative term. Mostly relative to bankruptcy.
One might venture to predict, with a degree of cautious optimism, that the year 2026 could prove to be the turning point. Though predictions, as any seasoned observer of human folly knows, are often little more than elaborate exercises in self-deception.
The announcement of this financial wizardry took place in Tokyo on January 29, 2026, during the first close of its Series A funding round. It’s like a reunion of long-lost friends, as this partnership initially blossomed back in September 2023. They are now deepening their relationship through the marvels of Sony Block Solutions Labs and the enigmatic Soneium Ethereum Layer 2. One can only imagine what kind of delightful shenanigans these two entities will concoct together!
But then there’s CoreWeave. Which, frankly, I hadn’t heard of until recently. It’s a bit like that quiet, slightly intense person at the party who turns out to be a genius coder. They’re aiming for the next generation of data centers, specifically built for this artificial intelligence thing everyone’s talking about. It’s a bold move. A very bold move. And, naturally, I’m deeply, deeply anxious about it.
Despite this…temporary setback, the so-called “on-chain data” – a realm inhabited by numbers and algorithms, far removed from the concerns of honest folk – whispers of a potential resurrection. Naturally.
